Commercialization Committee

Charter

The Commercialization Committee strives to:

  • Be the global communication hub between therapeutic societies, regulatory policy makers, institutional stem cell centres and industry for the advancement of clinical investigation in cell therapy and regenerative medicine.

Projects and Objectives

 

 


Committee Chair


 

Miguel Forte, MD, PhD
Chair
Bone Therapeutics
Brussels, Belgium

   

 

Committee Members


Sasha Aleksic, MSc
FUJIFILM Irvine Scientific
Irvine, CA, United States

Julie Allickson, PhD
Wake Forest Institute of Regenerative Medicine
Winston-Salem, NC, United States


 

Dolores Baksh, PhD
GE Healthcare
Marlborough, MA, United States

Gerhard Bauer, PhD
UC Davis
Sacramento, CA, United States
   
Bryan Choi, MD
SCRM
Incheon, South Korea
Dominic Clarke, PhD
HemaCare Corporation
Durham, NC, United States
   

Greg Crescenzi
GE Healthcare
Marlborough, MA, United States

Robert Deans, PhD
BlueRock Therapeutics 
Cambridge, MA, United States
   
Matthew Durdy, MBA
Cell and Gene Therapy Catapult
London, United Kingdom
Simon Ellison, MBA
World Courier
London, United Kingdom
  
John Fink, MBA
Pall Corporation
Boston, MA, United States

Mark Flower
Be The Match BioTherapies
Golden, CO, United States

   

Haro Hartounian, PhD
New Jersey Innovation Institute
Newark, NJ, United States

Anders Holm, PhD
Zelluna Immunotherapy
Oslo, Norway
   
Robert Jones
Cryoport
London, United Kingdom
Christopher Keller
Celularity
Warren, NJ, United States
   
Uma Lakshmipathy, PhD
Thermo Fisher Scientific
Carlsbad, CA, United States

Antonio Lee, PhD
CARM
Seongnam, Korea

   
Michael Lehmicke
Alliance for Regenerative Medicine
Washington, DC, Unites States
Bruce Levine, PhD
University of Pennsylvania
Philadelphia, PA, United States
  

Alex Lyness, PhD
West Pharmaceutical Services
Exton, PA, United States

Aby Mathew, PhD
BioLife Solutions
Bothell, WA, United States
   
Michael May, PhD
CCRM
Toronto, ON, Canada
Ruth McDermott
Satorius-Stedim Biotech
Royston, United Kingdom
   

Bill Milligan
Steminent Biotherapeutics
Vancouver, BC, Canada

Alison Moore, PhD
Allogene
San Francisco, CA, United States
   

Julie Murrell, PhD
MilliporeSigma
Bedford, MA, United States

Michitaka Nakao
FIRM
Tokyo, Japan
   

Benjamin Nelson, MBA
Fresenius Kabi
Lake Zurich, IL, United States

Carson Rhodes, MBA
Terumo BCT
Lakewood, CO, United States
   
Patrick Rivers, MBA
Aquilo Capital
San Francisco, CA, United States

Eric Roos, PhD
Thermo Fisher Scientific
Carlsbad, CA, United States

   

Alberto Santagastino
Lonza Biologics
Basel, Switzerland

Nathan Smith
Cell Therapies Pty Ltd
East Melbourne, VIC, Australia

   

Anthony Ting, PhD
Athersys
Cleveland, OH, United States

 

   

 


 




Ohad Karnieli, PhD, MBA
Pluristem Therapeutics
Haifa, Israel
Nathan Smith
Cell Therapies Pty Ltd
East Melbourne, VIC, AUS
Nathan Smith
Cell Therapies Pty Ltd
East Melbourne, VIC, AUS

© 2019 ISCT. All rights reserved. 
ISCT, and the ISCT logo are registered trademarks of the International Society for Cellular Therapy.
The BEACON and lighthouse logo is a service mark of the International Society for Cellular Therapy.

ISCT Privacy Policy